MA34642B1 - Anticorps dirigé contre le tweak humain et leurs utilisations - Google Patents

Anticorps dirigé contre le tweak humain et leurs utilisations

Info

Publication number
MA34642B1
MA34642B1 MA35867A MA35867A MA34642B1 MA 34642 B1 MA34642 B1 MA 34642B1 MA 35867 A MA35867 A MA 35867A MA 35867 A MA35867 A MA 35867A MA 34642 B1 MA34642 B1 MA 34642B1
Authority
MA
Morocco
Prior art keywords
tweak
diseases
directed against
antibodies directed
against human
Prior art date
Application number
MA35867A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34642B1 publication Critical patent/MA34642B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)

Abstract

L'invention concerne un anticorps se liant à TWEAK, caractérisé par la liaison à TWEAK, caractérisé en ce qu'il comprend en tant que domaine variable de la chaîne lourde un CDR3H choisi dans le groupe consistant en SEQ ID NO: 8, 16 ou 24, qui est utile pour le traitement du cancer ou de maladies auto-immunes, de la polyarthrite rhumatoïde, de la polyarthrite psoriasique, de maladies musculaires, par exemple la dystrophie musculaire, de la sclérose en plaque, de maladies rénales chroniques, de maladies osseuses, par exemple la dégénérescence osseuse dans des myélomes multiples, du lupus érythémateux disséminé, de la néphropathie lupique et de lésions vasculaires.
MA35867A 2010-10-05 2013-05-03 Anticorps dirigé contre le tweak humain et leurs utilisations MA34642B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05
PCT/EP2011/067070 WO2012045671A1 (fr) 2010-10-05 2011-09-30 Anticorps dirigé contre le tweak humain et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34642B1 true MA34642B1 (fr) 2013-11-02

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35867A MA34642B1 (fr) 2010-10-05 2013-05-03 Anticorps dirigé contre le tweak humain et leurs utilisations

Country Status (21)

Country Link
US (1) US9187564B2 (fr)
EP (1) EP2625200A1 (fr)
JP (1) JP5941049B2 (fr)
KR (1) KR101584416B1 (fr)
CN (1) CN103154029B (fr)
AR (1) AR083336A1 (fr)
AU (1) AU2011311673B2 (fr)
BR (1) BR112013007293A2 (fr)
CA (1) CA2809632A1 (fr)
CL (1) CL2013000901A1 (fr)
CR (1) CR20130108A (fr)
EA (1) EA201300418A1 (fr)
EC (1) ECSP13012542A (fr)
HK (1) HK1186195A1 (fr)
MA (1) MA34642B1 (fr)
MX (1) MX343114B (fr)
NZ (1) NZ607588A (fr)
PE (1) PE20131411A1 (fr)
SG (1) SG188605A1 (fr)
TW (1) TWI482630B (fr)
WO (1) WO2012045671A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5550799B2 (ja) * 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
CN102793921A (zh) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 用于治疗tweak 相关病症的方法
EP2332408B1 (fr) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Traitement de troubles neurologiques
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2824824A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Proteines monovalentes de liaison a l'antigene
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトtweak抗体
WO2015051234A2 (fr) * 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Antagonistes de tweak pour traiter la néphropathie lupique et l'atrophie musculaire
EP3174897B1 (fr) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Anticorps multi-spécifiques
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンg結合糖鎖構造に基づく臨床検査方法
AU7668696A (en) 1995-11-03 1997-05-22 Austin Research Institute, The Methods and compositions for the reduction of xenotransplantation rejection
DE69734397T2 (de) 1996-08-07 2006-07-06 Biogen Idec Ma Inc., Cambridge Tumor-nekrose-faktor ähnliches ligand
WO1998033523A1 (fr) 1997-01-31 1998-08-06 Biovation Limited Procede et molecules de vaccination
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
JP5550799B2 (ja) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
CN102793921A (zh) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 用于治疗tweak 相关病症的方法
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
WO2006052926A2 (fr) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
EP2332408B1 (fr) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Traitement de troubles neurologiques
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
CN102225200A (zh) 2005-03-07 2011-10-26 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
ES2507069T3 (es) 2005-05-27 2014-10-14 Biogen Idec Ma Inc. Anticuerpos de unión a TWEAK
WO2006130429A2 (fr) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Traitement du cancer
EP1904101A4 (fr) 2005-06-08 2011-06-15 Univ Duke Therapie a anticorps diriges contre cd19 a des fins de transplantation
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
CA2619825A1 (fr) 2005-08-19 2007-03-01 Centocor, Inc. Preparations d'anticorps resistants a la proteolyse
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
JP2013543383A (ja) 2013-12-05
WO2012045671A1 (fr) 2012-04-12
US20120121583A1 (en) 2012-05-17
EP2625200A1 (fr) 2013-08-14
AU2011311673B2 (en) 2015-09-17
JP5941049B2 (ja) 2016-06-29
TWI482630B (zh) 2015-05-01
MX2013003592A (es) 2013-05-31
AR083336A1 (es) 2013-02-21
TW201219054A (en) 2012-05-16
EA201300418A1 (ru) 2013-09-30
SG188605A1 (en) 2013-04-30
CA2809632A1 (fr) 2012-04-12
HK1186195A1 (zh) 2014-03-07
KR20130062369A (ko) 2013-06-12
ECSP13012542A (es) 2013-06-28
CL2013000901A1 (es) 2013-11-29
NZ607588A (en) 2014-02-28
US9187564B2 (en) 2015-11-17
CN103154029B (zh) 2015-11-25
BR112013007293A2 (pt) 2016-06-14
KR101584416B1 (ko) 2016-01-13
CN103154029A (zh) 2013-06-12
PE20131411A1 (es) 2013-12-16
CR20130108A (es) 2013-04-29
MX343114B (es) 2016-10-25
AU2011311673A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
MA34642B1 (fr) Anticorps dirigé contre le tweak humain et leurs utilisations
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MX2009006891A (es) Anticuerpos cd44.
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2009048537A3 (fr) Anticorps humanisé
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA31308B1 (fr) Anticorps antisclerostine.
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA30318B1 (fr) Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4
UA116614C2 (uk) Антитіло до фактора d і його застосування
TW200740844A (en) Novel MAdCAM antibodies
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EA201000424A1 (ru) Антитела к il-23
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA33387B1 (fr) Polypeptides et procede de traitement
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора